Treating tuberculosis without rifampicin: an open dilemma
Abstract
BACKGROUND: The World Health Organization recommends the same treatment regimens for rifampicin-monoresistant (RR) and multidrug-resistant (MDR) TB. Aside of resistance, rifampicin cannot be used in all patients because of allergy, intolerance or drug-to-drug interactions (here called "functional" rifampicin mono-resistance or fRR).
OBJECTIVES: Given the uncertainty on the best way to treat these forms of TB, we performed a literature review assessing the epidemiology and diagnostic tools for RR and fRR-TB, as well as treatment options and costs of the potential treatments.
SOURCES: We performed a narrative review of the English-language literature by using the terms "tuberculosis"/"rifampicin" and "mono-resistance"/"rifampicin"/"tuberculosis" in the time frame 1960-2025; secondary articles were also manually evaluated from selected papers' bibliographies.
CONTENT: We described the role of rifampicin in the antitubercular armamentarium, the epidemiology of RR, the laboratory methods used for detecting rifampicin resistance, the evolution of guidelines on the topic, as well as the studies that reported the use of non-standard regimens for patients with RR or fRR. We summarized the potential options with their pros and cons and suggested a potential flowchart in such scenarios.
IMPLICATIONS: WHO-recommended regimens for RR/MDR are the key treatments for patients with RR or fRR-TB: despite the heterogeneity of available data, we identified scenarios where rifampicin can be…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.